DÄ internationalArchive25/2020The effects of differing invitation models on the uptake of immunological fecal occult blood testing

Original article

The effects of differing invitation models on the uptake of immunological fecal occult blood testing

Results from a randomized controlled trial

Dtsch Arztebl Int 2020; 117: 423-30. DOI: 10.3238/arztebl.2020.0423

Gruner, L F; Hoffmeister, M; Ludwig, L; Meny, S; Brenner, H

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Abteilung Klinische Epidemiologie und Alternsforschung, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg: Laura Fiona Gruner, M. Sc., PD Dr. sc. hum. Michael Hoffmeister, Prof. Dr. med. Hermann Brenner
Universität Heidelberg, Medizinische Fakultät Heidelberg: Laura Fiona Gruner, M. Sc.
Gastroenterologische Schwerpunktpraxis, Dornstadt: Prof. Dr. med. Leopold Ludwig
AOK Baden-Württemberg, Stuttgart: Stefan Meny, M. Sc.
Abteilung Präventive Onkologie, Deutsches Krebsforschungszentrum (DKFZ) und Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg: Prof. Dr. med. Hermann Brenner
Deutsches Konsortium für Translationale Krebsforschung (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Heidelberg: Prof. Dr. med. Hermann Brenner
1.Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (eds.): Krebs in Deutschland für 2015/2016. 12. Edition. Berlin: Robert Koch-Institut 2019.
2.Shaukat A, Mongin SJ, Geisser MS, et al.: Long-term mortality after screening for colorectal cancer. N Engl J Med 2013; 369: 1106–14 CrossRef MEDLINE
3.Brenner H, Stock C, Hoffmeister M: Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014; 348: g2467 CrossRef MEDLINE PubMed Central
4.Buskermolen M, Cenin DR, Helsingen LM, et al.: Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ 2019; 367: l5383 CrossRef MEDLINE PubMed Central
5.Gruner LF, Hoffmeister M, Ludwig L, Brenner H: Effect of various invitation schemes on the use of fecal immunochemical tests for colorectal cancer screening: protocol for a randomized controlled trial. JMIR Res Protoc 2020; 9: e16413 CrossRef MEDLINE PubMed Central
6.Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332 CrossRef MEDLINE PubMed Central
7.Fraser CG, Allison JE, Young GP, Halloran SP, Seaman HE: Improving the reporting of evaluations of faecal immunochemical tests for haemoglobin: the FITTER standard and checklist. Eur J Cancer Prev 2015; 24: 24–6 CrossRef MEDLINE
8.Hoffmeister M, Holleczek B, Zwink N, Stock C, Stegmaier C, Brenner H: Screening for bowel cancer: increasing participation via personal invitation—a randomized intervention study. Dtsch Arztebl Int 2017; 114: 87– 93 VOLLTEXT
9.Akram A, Juang D, Bustamante R, et al.: Replacing the guaiac fecal occult blood test with the fecal immunochemical test increases proportion of individuals screened in a large healthcare setting. Clin Gastroenterol Hepatol 2017; 15: 1265–70. e1 CrossRef MEDLINE
10.Senore C, Basu P, Anttila A, et al.: Performance of colorectal cancer screening in the European Union member states: data from the second European screening report. Gut 2019; 68: 1232–44 CrossRef MEDLINE
11.Gemeinsamer Bundes­aus­schuss (G-BA): Richtlinie des Gemeinsamen Bundes­aus­schusses für organisierte Krebsfrüherkennungsprogramme. Geänderte Fassung vom 22.11.2018, in Kraft getreten am 01.07.2019. www.g-ba.de/downloads/62-492-1844/oKFE-RL-2018-11-22-iK-2019-07-01.pdf (last accessed on 5 July 2019)
12.Gemeinsamer Bundes­aus­schuss (G-BA): Der iFOBT im Darmkrebs-Screening: Ergebnisse der medizinischen Laboratorien für das Jahr 2018. www.g-ba.de/downloads/17-98-4777/2019-03-25_G-BA_iFOBT_Quartalsbericht_2018_.pdf (last accessed on 17 June 2019).
13.Kapidzic A, Grobbee EJ, Hol L, et al.: Attendance and yield over three rounds of population-based fecal immunochemical test screening. Am J Gastroenterol 2014; 109: 1257–64 CrossRef MEDLINE
14.Kapidzic A, van Roon AH, van Leerdam ME, et al.: Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. Gut 2017; 66: 118–23 CrossRef MEDLINE
15.van Roon AH, Hol L, Wilschut JA, et al.: Advance notification letters increase adherence in colorectal cancer screening: a population-based randomized trial. Prev Med 2011; 52: 448–51 CrossRef MEDLINE
16.Erasmus MC – NKI / AvL: Monitor 2017, national monitoring of the colorectal cancer screening programme. www.rivm.nl/sites/default/files/2018-11/DarmMon2017-Engels5.pdf (last accessed on 20 January 2020).
17.Weigl K, Tikk K, Hoffmeister M, et al.: Prevalence of a first-degree relative with colorectal cancer and uptake of screening among persons 40 to 54 years old. Clin Gastroenterol Hepatol 2019. pii: S1542–3565(19)31384–9. (Epub ahead of print) CrossRef MEDLINE
18.Stock C, Ihle P, Schubert I, Brenner H: Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort. Endoscopy 2011; 43: 771–81 CrossRef MEDLINE
19.Yang C, Sriranjan V, Abou-Setta AM, Poluha W, Walker JR, Singh H: Anxiety associated with colonoscopy and flexible sigmoidoscopy: a systematic review. Am J Gastroenterol 2018; 113: 1810–8 CrossRef MEDLINE PubMed Central
20.Brenner H, Zwink N, Ludwig L, Hoffmeister M: Should screening colonoscopy be offered from age 50? Results from a statewide pilot project, and from a randomized intervention study. Dtsch Arztebl Int 2017; 114: 94–100 VOLLTEXT